Key result
Mitral valve repair provides better early and late outcomes than replacement for infective endocarditis, though this superiority is driven by cohort studies from highly experienced centers.
Why the study?
Does mitral valve repair improve early and late survival compared to mitral valve replacement in patients with infective endocarditis?
Does mitral valve repair improve early and late survival compared to mitral valve replacement in patients with infective endocarditis?
Answers are grounded in this paper and cite their sources.
The decision to perform mitral valve repair versus replacement in infective endocarditis should be individualized based on tissue damage and surgical expertise, guided by a multidisciplinary EndoTeam.
The meta-analysis by He and collaborators [has the worth to cover, as much as possible, a gap of scientific evidence where conducting a randomized trial appears very complex for ethical and logistical reasons. The authors concluded that mitral valve repair (MVP) provide better pooled results, both early and late, with respect to mitral valve replacement (MVR). However, the superiority of MVP is driven by some single large cohort-studies where surgeons had wide experience in the field of MVP for IE. This finding is also confirmed by other studies. But if mitral repair produces such a better short- and long-term survival than replacement, why are there no clear indications from consensus and guidelines pushing surgeons toward the pursuit of a reconstructive procedure at almost any cost? We wonder but to repair or not to repair, is that really the question? The AATS consensus suggests to repair “whenever possible” but without providing more specific indications. If the two primary goals of surgery are total removal of infected tissues and reconstruction of cardiac morphology, including repair or replacement of the affected valve(s), probably MVP as to perform in case of less extensive tissue detriment by the infection. In more wide valve involvement, MVP may be the choice but only in very expert hands and in Centers with very large volume of valve repairing. This decision cannot therefore be the result of the choice of an individual but must derive from a careful multidisciplinary discussion to be held in an EndoTeam.
No takes yet. Share an insight, caveat, or question.
Mauro et al. (2021) conducted an editorial in Valve Endocarditis. Mitral valve repair (MVP) vs. Mitral valve replacement (MVR) was evaluated on Early and late outcomes (survival). Mitral valve repair provides better early and late outcomes than replacement for infective endocarditis, though this superiority is driven by cohort studies from highly experienced centers.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: